Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Bivalent boosters: Aotearoa’s winter defence against COVID-19
+Practice
In print
Vaccines
Bivalent boosters: Aotearoa’s winter defence against COVID-19
Wednesday 10 May 2023, 12:35 AM

A “winter wave” of COVID-19 is likely to burden the healthcare system [Image: Osman Rana on Unsplash]
Changes to the COVID-19 booster can be thought of as similar to the way the influenza vaccine is changed annually – the bivalent booster is the first step along that road
Key points, COVID-19 variants are increasingly immune-evasive.
Waning immunity from previous boosters has necessitated the introduction of a bivalent COVID-19 v, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
- Tenforde MW, Weber ZA, Natarajan K, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults – VISION Network, Nine States, September–November, 2022. MMWR Morb Mortal Wkly Rep 2022;71(5152):1616–24.
- Surie D, DeCuir J, Zhu Y, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated hospitalization among immunocompetent adults aged ≥65 years – IVY Network, 18 States, September 8–November 30, 2022. MMWR Morb Mortal Wkly Rep 2022;71(5152):1625–30.
- Lin D-Y, Xu Y, Gu Y, et al. Effectiveness of bivalent boosters against severe Omicron infection. N Engl J Med 2023;388:764–66.
- Link-Gelles R, Ciesla AA, Roper LE, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults – increasing community access to testing program, United States, December 2022–January 2023. MMWR Morb Mortal Wkly Rep 2023;72(5):119–24.